-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Eli Lilly and Incyte jointly announced that the co-developed JAK inhibitor baricitinib showed excellent results in two phase III clinical studies, and the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) supported the European Union Marketed for the treatment of adult patients with severe alopecia area.
The data show that baricitinib is a once-daily oral JAK inhibitor originally developed by Incy.
In December 2009, Eli Lilly and Incyte entered into an agreement to co-develop and commercialize the product in a deal totaling $755 million, including $90 million upfront and up to $665 million in mil.
In March 2020, baricitinib was granted breakthrough therapy designation by the FDA for the treatment of severe alopecia areata in adults; in February 2022, it was granted priority review by the F.
If successfully approved, it will become the world's first JAK inhibitor for the treatment of severe alopecia area.
It is understood that hair loss has become a global "time diseas.
According to the World Health Organization, about 6 billion of the world's 7 billion people suffer from hair lo.
Previously, the data analysis agency Market Date Forecast conservatively estimated that the global hair loss market will reach at least US$81 billion in 2021, and is expected to grow to US$144 billion (about 86 billion yuan) in 2026, with an average annual compound growth rate of
According to the cause of hair loss, hair loss can be roughly divided into androgenetic alopecia, alopecia areata, and hair loss caused by anticancer drug treatme.
Among them, androgenetic alopecia (AGA) has the highest incidence, also known as male pattern baldness, which mainly affects the front, middle and top of the sca.
At present, the hair-raising, hair-transplanting and other industries derived from hair loss are huge in the domestic mark.
According to data, the number of people with hair loss in China has exceeded 250 milli.
The domestic hair loss consumption industry has entered a stage of rapid development from the early stage of cultivation, and is in a period of high prosperi.
According to data from Huatai Securities, my country's hair loss treatment market will be about 20 billion yuan in 2020, and it is expected that the hair loss treatment market will reach 161 billion yuan in 203
However, compared with the expanding market, there is still a big gap in the real hair loss drug mark.
At present, in the field of drug treatment for hair loss, even if baricitinib is successfully approved for marketing, the almost blank tens of billions of hair loss drug treatment market has just been open.
However, attracted by the huge market prospects, the industry expects that more and more pharmaceutical companies will join the fie.
It is understood that some JAK inhibitors have been developed in China for the treatment of AA, such as Jaketinib of Zejing Medicine and SHR0302 of Ruishi Biotechnolo.
Among them, Jacktinib is a small molecule inhibitor of JAK kinase independently developed by Zejing Bio through its drug stabilization technology in its precise small molecule new drug research and development and industrialization platfo.
It has two dosage forms: tablet and cre.
In 2020, Zejing Bio has already started Phase 2 clinical trials of Jacktinib tablets in the treatment of severe AA and intermediate and high-risk myelofibrosis, as well as two Phase 1 trials for graft-versus-host disease and idiopathic pulmonary fibros.
In addition, Zejing Bio is also conducting a phase I/II clinical trial of jacktinib hydrochloride cream in the treatment of mild to moderate AA and mild to moderate atopic dermatit.
In addition, SHR0302, a JAK1 inhibitor independently developed by Hengrui, has also been approved for clinical trials in ulcerative colitis, Crohn's disease, atopic dermatitis, rheumatoid arthritis, ankylosing spondylitis and alopecia area.
Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyo.
Click to enter the exhibition page
The data show that baricitinib is a once-daily oral JAK inhibitor originally developed by Incy.
In December 2009, Eli Lilly and Incyte entered into an agreement to co-develop and commercialize the product in a deal totaling $755 million, including $90 million upfront and up to $665 million in mil.
In March 2020, baricitinib was granted breakthrough therapy designation by the FDA for the treatment of severe alopecia areata in adults; in February 2022, it was granted priority review by the F.
If successfully approved, it will become the world's first JAK inhibitor for the treatment of severe alopecia area.
It is understood that hair loss has become a global "time diseas.
According to the World Health Organization, about 6 billion of the world's 7 billion people suffer from hair lo.
Previously, the data analysis agency Market Date Forecast conservatively estimated that the global hair loss market will reach at least US$81 billion in 2021, and is expected to grow to US$144 billion (about 86 billion yuan) in 2026, with an average annual compound growth rate of
According to the cause of hair loss, hair loss can be roughly divided into androgenetic alopecia, alopecia areata, and hair loss caused by anticancer drug treatme.
Among them, androgenetic alopecia (AGA) has the highest incidence, also known as male pattern baldness, which mainly affects the front, middle and top of the sca.
At present, the hair-raising, hair-transplanting and other industries derived from hair loss are huge in the domestic mark.
According to data, the number of people with hair loss in China has exceeded 250 milli.
The domestic hair loss consumption industry has entered a stage of rapid development from the early stage of cultivation, and is in a period of high prosperi.
According to data from Huatai Securities, my country's hair loss treatment market will be about 20 billion yuan in 2020, and it is expected that the hair loss treatment market will reach 161 billion yuan in 203
However, compared with the expanding market, there is still a big gap in the real hair loss drug mark.
At present, in the field of drug treatment for hair loss, even if baricitinib is successfully approved for marketing, the almost blank tens of billions of hair loss drug treatment market has just been open.
However, attracted by the huge market prospects, the industry expects that more and more pharmaceutical companies will join the fie.
It is understood that some JAK inhibitors have been developed in China for the treatment of AA, such as Jaketinib of Zejing Medicine and SHR0302 of Ruishi Biotechnolo.
Among them, Jacktinib is a small molecule inhibitor of JAK kinase independently developed by Zejing Bio through its drug stabilization technology in its precise small molecule new drug research and development and industrialization platfo.
It has two dosage forms: tablet and cre.
In 2020, Zejing Bio has already started Phase 2 clinical trials of Jacktinib tablets in the treatment of severe AA and intermediate and high-risk myelofibrosis, as well as two Phase 1 trials for graft-versus-host disease and idiopathic pulmonary fibros.
In addition, Zejing Bio is also conducting a phase I/II clinical trial of jacktinib hydrochloride cream in the treatment of mild to moderate AA and mild to moderate atopic dermatit.
In addition, SHR0302, a JAK1 inhibitor independently developed by Hengrui, has also been approved for clinical trials in ulcerative colitis, Crohn's disease, atopic dermatitis, rheumatoid arthritis, ankylosing spondylitis and alopecia area.
Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyo.
Click to enter the exhibition page
